Ofloxacin-Pos (Ofloxacin)

Ofloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. By inhibiting these targets, the drug prevents bacterial cell division and leads to rapid bacterial death, providing a bactericidal effect against a broad range of ocular pathogens.

The dosing regimen for Ofloxacin-Pos is determined by the prescribing clinician based on the specific infection, severity and patient factors. Typical regimens involve one to two drops per eye at defined intervals, but the exact schedule should always follow the healthcare professional’s instructions.

Safety data for Ofloxacin-Pos in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified prescriber.

To place an order, visit the product page on gnhindia.com, enter the required quantity and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ofloxacin belongs to the fluoroquinolone class, offering broad‑spectrum activity against both Gram‑negative and Gram‑positive bacteria. Compared with older agents such as chloramphenicol or erythromycin, ofloxacin often provides faster bacterial eradication and a lower risk of resistance, though choice should be guided by local susceptibility patterns and clinician preference.

Store Ofloxacin-Pos at ambient temperature, preferably below 25 °C, in its original packaging. Protect the container from direct sunlight, moisture and extreme temperatures. Keep the product out of reach of children and discard any solution that appears discoloured or cloudy.

The solution is applied topically to the affected eye(s) using a sterile dropper. The patient should wash their hands, tilt the head back, pull down the lower eyelid, and place the prescribed number of drops into the conjunctival sac. The eye should be closed gently for a few seconds to allow absorption.

Serious adverse events, although rare, include corneal ulceration, severe allergic reactions such as eyelid edema, Stevens‑Johnson syndrome, toxic epidermal necrolysis and significant vision loss. Any sudden worsening of ocular symptoms or systemic allergic signs should prompt immediate medical evaluation.

Patients with a known hypersensitivity to ofloxacin, other fluoroquinolones, or any component of the formulation should avoid the product. It is also contraindicated in individuals where a severe ocular surface disease requires alternative therapy, and caution is advised in pregnant or nursing women until benefits are clearly established.